ETF Building Blocks ChannelDrug Price Debate May Not Hinder Biotech ETFs After AllBy Tom LydonSeptember 16, 2021
ETF Building Blocks ChannelBiotech Stocks Have Colds, but They Can HealBy Tom LydonSeptember 13, 2021
ETF Building Blocks ChannelWill the Biotech Space Consolidate in the Back Half of the Year?By Tom LydonJuly 14, 2021
ETF Building Blocks ChannelPost-Pandemic Healthcare Could Feature More Biotech M&ABy Tom LydonJune 10, 2021
ETF Building Blocks ChannelAs Biotech Consolidation Heats up, ‘SBIO’ Could Be a WinnerBy Tom LydonMay 24, 2021
ETF Building Blocks ChannelALPS ‘SBIO’ ETF: Trial Progress Meets Investing SuccessBy Tom LydonJanuary 25, 2021
ETF Building Blocks ChannelDon’t Miss Out on Rampant Biotech Mergers with the SBIO ETFBy Tom LydonJanuary 13, 2021
Innovative ETFs ChannelConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021By Max ChenDecember 31, 2020
ETF Building Blocks ChannelHow Increased FDA Activity Can Benefit ETFs in Your PortfolioBy Tom LydonNovember 19, 2020
ETF Building Blocks ChannelMore than Just COVID: Hot ETFs for Medical BreakthroughsBy Tom LydonNovember 5, 2020
ETF Building Blocks ChannelPost-Election Considerations for a Nifty Biotech ETFBy Tom LydonOctober 7, 2020
ETF Building Blocks ChannelA Healthcare ETF Could Benefit From Index ReshufflingBy Tom LydonJune 23, 2020
ETF Building Blocks ChannelBiotech ETF Doesn’t Need Coronavirus Vaccines to SoarBy Tom LydonJune 2, 2020
